<DOC>
	<DOCNO>NCT02594384</DOCNO>
	<brief_summary>This Phase 1 dose exploration study LAM-002A administer mouth patient relapse refractory B-cell NHL . Safety , tolerability , pharmacokinetics ( PK ) preliminary activity evaluate .</brief_summary>
	<brief_title>A Phase I Dose Escalation Study Safety Pharmacokinetics LAM-002A In Patients With Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>LAM-002A supply 25 mg capsule administer twice daily ( BID ) mouth cycle length 28 day . Patients advise take dos time day , approximately 12 hour apart empty stomach ( food within 2 hour prior dose , within 2 hour dose ) . A 3 + 3 design utilized define maximum tolerate dose ( MTD ) . The MTD define high dose 1 6 patient ( i.e. , &lt; 33 % ) experience dose-limiting toxicity ( DLT ) dose cohort . Once dose schedule establish , additional patient treat well characterize safety , tolerability , preliminary anti-tumor activity , PK pharmacodynamics study drug .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<criteria>1 . Able understand comply protocol requirement sign informed consent document . 2 . Confirmed diagnosis Bcell NonHodgkin 's lymphoma limit follicular lymphoma ( FL ) , DLBCL , mantle cell lymphoma ( MCL ) , marginal zone lymphoma ( MZL ) CLL/SLL progress standard curative measure exist longer effective . Prior therapy must include rituximabbased regimen . 3 . Patients DLBCL must progress transplant , unwilling , unable appropriate candidate autologous stem cell transplant 4 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 2 less . 5 . Adequate organ marrow function . 6 . Able swallow oral capsule without difficulty . 9 . Acceptable birth control . 10 . Women childbearing potential ( WCBP ) must negative serum urine pregnancy test screening . 1 . Patients central nervous system ( CNS ) lymphoma eligible trial unless disease treat subject remain without symptom active CNS lymphoma . 2 . Not recovered toxicity due prior therapy . 3 . Other uncontrolled significant illness . 4 . History malabsorption gastrointestinal ( GI ) disease may significantly alter absorption apilimod 5 . The patient undergone major surgery within 28 day prior first dose study drug . 6 . Past history tuberculosis ( TB ) active infection TB , human immunodeficiency virus ( HIV ) , hepatitis B hepatitis C. 7 . The patient lactate breast feeding . 8 . Unable unwilling abide study protocol cooperate fully Investigator designee . This shortened list additional criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>Safety</keyword>
	<keyword>Apilimod dimesylate</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Non-Hodgkin 's Lymphoma</keyword>
</DOC>